Prognostic significance of fever-induced Brugada syndrome

Jul 31, 2016 , Category : Cardiology Abstracts

Prognostic significance of fever-induced Brugada syndrome

Yuka Mizusawa, MD, Hiroshi Morita, MD, PhD, Arnon Adler, MD, PhD, Ofer Havakuk, MD, Aurélie Thollet, PhD, Philippe Maury, MD, Dao W. Wang, MD, PhD, Kui Hong, MD, PhD, Estelle Gandjbakhch, MD, PhD, Frédéric Sacher, MD, PhD, Dan Hu, MD, PhD, Ahmad S. Amin, MD, PhD, Najim Lahrouchi, MD, Hanno L. Tan, MD, PhD, Charles Antzelevitch, PhD, FHRS, Vincent Probst, MD, PhD, Sami Viskin, MD, Arthur A.M. Wilde, MD, PhD

Heart Rhythm July 2016 Volume 13, Issue 7, Pages 1515–1520

Background
In Brugada syndrome (BrS), spontaneous type 1 electrocardiogram (ECG) is an established risk marker for fatal arrhythmias whereas drug-induced type 1 ECG shows a relatively benign prognosis. No study has analyzed the prognosis of fever-induced type 1 ECG (F-type1) in a large BrS cohort.

Objectives
The objectives of this study were to assess the prognosis of F-type1 in asymptomatic BrS and to compare the effects of fever and drugs on ECG parameters.

Methods
One hundred twelve patients with BrS who developed F-type1 were retrospectively enrolled. Prognosis was evaluated in 88 asymptomatic patients. In a subgroup (n = 52), ECG parameters of multiple ECGs (at baseline, during fever, and after drug challenge) were analyzed.

Results
Eighty-eight asymptomatic patients had a mean age of 45.8 ± 18.7 years, and 71.6% (67 of 88) were men. Twenty-one percent (18 of 88) had a family history of sudden cardiac death, and 26.4% (14 of 53) carried a pathogenic SCN5A mutation. Drug challenge was positive in 29 of 36 patients tested (80.6%). The risk of ventricular fibrillation in asymptomatic patients was 0.9%/y (3 of 88; 43.6 ± 37.4 months). ST-segment elevation in lead V2 during fever and after drug challenge was not significantly different (0.41 ± 0.21 ms during fever and 0.40 ± 0.30 ms after drug challenge; P > .05). Fever shortened the PR interval compared to baseline, whereas drug challenge resulted in prolonged PR interval and QRS duration (PR interval: 169 ± 29 ms at baseline, 148 ± 45 ms during fever, and 202 ± 35 ms after drug challenge; QRS duration: 97 ± 18 ms at baseline, 92 ± 28 ms during fever, and 117 ± 21 ms after drug challenge).

Conclusion
Patients with BrS who develop F-type1 are at risk of arrhythmic events. F-type1 appears to develop through a more complex mechanism as compared with drug-induced type 1 ECG.


Thoughts about the post

Leave a comment



Please fill out all required fields